Lung cancer patients get new hope from Drug-Radiation combo
NCT ID NCT02839265
First seen Apr 29, 2026 · Last updated Jun 23, 2026 · Updated 9 times
Summary
This phase 2 trial tested a combination of FLT3 ligand immunotherapy (CDX-301) and stereotactic body radiotherapy (SBRT) in 33 adults with advanced non-small cell lung cancer that had worsened after standard treatments. The goal was to see if this approach could slow cancer growth. Patients received daily injections of the immunotherapy for five days starting with the first radiation session. The study measured how many patients were alive without their cancer getting worse after four months.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER (NSCLC) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Montefiore Medical Center
The Bronx, New York, 10467, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
FLT3 ligand (CDX-301) and stereotactic body radiotherapy
What this could lead to
If it works, this combination could offer a new treatment option for advanced lung cancer patients who have run out of standard therapies.
What could go wrong
This is a small, early-phase trial with only 33 participants, so results may not apply to everyone. The treatment also carries risks of serious side effects from both the drug and radiation.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.